Patent GB-860888-A (GB)
Title: Soya phosphatides and therapeutic compositions containing them
IPC: C07F9/10
Filed: 1957-03-11
Abstract: A stable soya phosphatide fraction which does not depress blood pressure when injected into an sthetized cats and which is a satisfactory emulsifier for the oil used in a therapeutic fat product (see Group VI) is obtained by adsorbing the undesirable reactive materials present in a solution of a soya phosphatide fraction, obtained by extracting soya phosphatides with a monohydric lower molecular weight saturated aliphatic alcohol of 1 to 8 carbon atoms and of 85 to 100% concentration, by contacting said solution with an adsorbent selected from aluminium oxide, magnesium oxide or activated carbon, and then recovering the stable soya phosphatide fraction. Ethanol is the preferred monohydric alcohol but methanol, propanol and isopropanol or mixtures thereof are also specified.  In a preferred embodiment a suitable product is obtained by stirring one part by weight of the ethanol soluble portion of soya phosphatide in about ten parts by volume of ethanol with about 2 parts by weight of aluminium oxide at room temperature, filtering off the aluminium oxide and then removing the alcohol under reduced pressure.  When, however, the amount of aluminium oxide is reduced to 1.5 parts by weight, the product obtained is unsatisfactory.  The activated carbon used as adsorbent should be a non-acid carbon.  In another embodiment a commercial solid soya phosphatide mixture having a lower oil content than commercial lecithins is extracted three times with absolute ethanol at room temperature, the extracts are clarified by gravity filtration and then concentrated under reduced pressure and put on a column of aluminium oxide which is then eluted with 95% aqueous ethanol to yield an eluate fraction from which a suitable phosphatide fraction is recovered as residue after removing the alcohol under reduced pressure.  It is stated that in the stable soya phosphatide product the proportion of lecithin has been increased while the proportion of cephalin components, especially the inositol, has been reduced.ALSO:A therapeutic fat product suitable for intravenous use in human beings comprises a metabolizable non-toxic fixed oil emulsified in an aqueous vehicle by a stable soya phosphatide fraction which does not depress blood pressure when injected into an sthetized cats and which is obtainable by adsorbing the undesirable reactive materials present in a solution of a soya phosphatide fraction, obtained by extracting soya phosphatides with a monohydric lower molecular weight saturated aliphatic alcohol of 1 to 8 carbon atoms, preferably ethanol, and of 85 to 100% concentration, by contacting said solution with an adsorbent selected from aluminium oxide, magnesium oxide or activated carbon, and then recovering the stable soya phosphatide fraction (see Group IV (b)).  Isotonic agents, e.g. metabolizable sugars such as glucose and fructose or polyhydroxy alcohols, e.g. sorbitol, and an antioxidant, especially a metabolizable antioxidant of the phenolic type, e.g. a combination of tertiary butyl-4-hydroxy anisole, propyl gallate and citric acid may also be added and an ethylene oxide-polypropylene glycol condensation product in which the propylene units are located in non-terminal positions and are connected to each other in a chain may be added as co-emulsifier.  Suitable fixed oils are naturally occurring vegetable and animal oils, and synthetic oils, cottonseed oil and olive oil being preferred.